Fritextsökning
Innehållstyper
-
Elekta får USA-order
Strålterapibolagets aktie stiger i samband med en order av flera cancervårdslösningar till Providence Health & Services.
-
Fewer visitors but satisfied exhibitors
Biotech Forum Scanlab attracted fewer visitors than in 2008. Exhibition manager Bo Rasmussen is content, claiming that the exhibitors are very satisfied.
-
PCG rekryterar rådgivare och dotterbolags-vd
Kontraktforskningsbolaget Pharma Consulting Group, PCG, har rekryterat Gunnar Danielsson som Senior Regulatory Advisor. Henrik Persson blir vd för datafångstdel...
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
Samarbete med universitet ska gynna Novo
I Combine samarbetar sex svenska universitet för att skapa bättre förståelse kring inflammatoriska sjukdomar. Bolaget ska nu delta i ett projekt för att arbeta ...
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be ...
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Xvivo till Ryssland
Får godkänt för perfusionsvätskorna Perfadex och Steen Solution.
-
Take off for this year's fair
More visitors than previously were preregistered when Scanlab and Biotech Forum opened today. But the future of the exhibitions and their design is uncertain.
-
Mathematician new dean at DTU
On January 1st the Technical University of Denmark, DTU, got a new dean, recruited from the department of Mathematics.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Datorn som matchmaker
Datorbaserade modeller kan användas för att förstå interaktioner mellan två läkemedel eller förutsäga biverkningar. - Det blir också möjligt att identifiera pro...
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Polymer guru new dean at DTU
The Technical University of Denmark, DTU, has appointed a well-known profile from the Polymer Center as a new dean.
-
VTT in brief
VTT is a broad science cluster with research within applied materials, chemical and biochemical processes, energy, industrial systems management, information an...
-
Apoteksutredning föreslår flera åtgärder för säkerhet
Utredaren Åsa Kullgren föreslår flera förändringar som ska förbättra säkerheten och tillgängligheten på apoteksmarknaden.
-
Age essential when testing drugs
Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established...
-
Getinge skaffar ny finanschef
Pernille Fabricius sköter ekonomin på medtechbolaget.
-
KI innovations väljer ut bolag
Efter stöd från Vinnova stärker KI innovations nu sitt inkubatorserbjudande till life sciencebolag. Sex bolag har valts ut till inkubatorsprogrammet.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and on...
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Woman deficit in Swedish research
The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.
BREAKING